The FDA releases biosimilar-naming draft guidance; PD1 drugs linked to a rare type of diabetes; Amgen's PCSK9 inhibitor faces approval decision
The compliance "university" aims to help healthcare agencies and publishers stay up to date on the latest regulatory changes.
Medicaid officials urged to expand access to hepatitis-C drugs; Perrigo is looking to make acquisitions; Sarepta's experimental therapy gets priority review
Longtime ICC leader Viviano moves to the client side to help the start-up build its marketing team and become a commercial contender.
The cloud technology firm announced it will acquire Avalere in a move aimed at growing its relationships with pharma.
US patent office declines to review two Ampyra patents; the FDA expands indication for Promacta; the Biosimilars Council argues against CMS proposal for biosimilar coding
Publicis Healthcare Singapore will launch in September.
AstraZeneca inks cancer development deal; beta-blockers may increase survival in ovarian-cancer patients; OPDP finds corrective ads are ineffective
Contrary to popular belief, Addyi is not the female Viagra. That's the message drug-maker Sprout must get across to doctors and patients in the coming weeks.
The FDA encourages clinical testing of testosterone; Google spins out its life-sciences business; Novartis buys remaining rights to Arzerra
Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.